Published in Gastroenterology on May 01, 2002
Liver cirrhosis. Lancet (2008) 6.11
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest (2007) 4.41
Viral hepatitis in HIV infection. N Engl J Med (2007) 4.18
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology (2012) 3.19
Hepatitis C virus infection protein network. Mol Syst Biol (2008) 2.91
Evolving therapies for liver fibrosis. J Clin Invest (2013) 2.59
Academic health center management of chronic diseases through knowledge networks: Project ECHO. Acad Med (2007) 2.18
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology (2014) 2.17
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology (2009) 2.07
An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol (2015) 1.86
Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology (2008) 1.85
Hepatic inflammation and fibrosis: functional links and key pathways. Hepatology (2015) 1.68
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology (2002) 1.60
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57
Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody. Liver Int (2008) 1.47
Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis (2008) 1.39
Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ (2003) 1.37
Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther (2005) 1.33
Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology (2010) 1.32
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut (2005) 1.24
Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Curr Cancer Drug Targets (2012) 1.23
Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction (2008) 1.20
Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res (2014) 1.17
Advances in antifibrotic therapy. Expert Rev Gastroenterol Hepatol (2008) 1.17
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist. Proc Natl Acad Sci U S A (2012) 1.16
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Reversibility of liver fibrosis. Fibrogenesis Tissue Repair (2012) 1.13
Hepatitis C, stigma and cure. World J Gastroenterol (2013) 1.13
Review of MR elastography applications and recent developments. J Magn Reson Imaging (2012) 1.12
Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. Hepat Mon (2012) 1.10
Automated liver stiffness measurements with magnetic resonance elastography. J Magn Reson Imaging (2012) 1.10
Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol (2010) 1.08
MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-α. PLoS One (2013) 1.08
Death receptors as targets for anti-cancer therapy. J Cell Mol Med (2008) 1.07
PAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: role of hepatocyte division. Am J Physiol Gastrointest Liver Physiol (2010) 1.06
Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol (2008) 1.04
Management of chronic hepatitis C. Postgrad Med J (2005) 1.03
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology (2009) 1.03
Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Int J Hepatol (2012) 1.02
New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J Gastroenterol Hepatol (2008) 1.00
Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst (2007) 0.99
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol (2005) 0.99
Antiviral therapy leads to histological improvement of HBeAg-negative chronic hepatitis B patients. Ann Gastroenterol (2015) 0.98
Advances in alcoholic liver disease. Curr Gastroenterol Rep (2011) 0.98
Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98
Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci (2003) 0.97
Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood) (2012) 0.96
Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96
Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci (2014) 0.95
Hepatitis C screening: getting it right. Hepatology (2012) 0.94
Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int (2010) 0.93
Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. PLoS One (2012) 0.92
Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol (2013) 0.92
The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother (2004) 0.92
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther (2008) 0.91
Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection. Clin Exp Immunol (2005) 0.91
Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis (2011) 0.91
A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. J Gastroenterol (2011) 0.90
The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B. Clin Mol Hepatol (2015) 0.90
Reversal of liver fibrosis. Saudi J Gastroenterol (2009) 0.90
Automated liver elasticity calculation for MR elastography. J Magn Reson Imaging (2015) 0.90
Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. AIDS Patient Care STDS (2012) 0.89
Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C. Clin Trials (2011) 0.89
Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. Br J Gen Pract (2006) 0.89
Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88
Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy. Eur J Gastroenterol Hepatol (2009) 0.87
Prediction of fibrosis progression in chronic viral hepatitis. Clin Mol Hepatol (2014) 0.87
Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol (2015) 0.87
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol (2009) 0.87
Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol (2014) 0.87
Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). Br J Clin Pharmacol (2009) 0.87
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection. J Hepatol (2016) 0.87
The management of patients awaiting liver transplantation. Nat Rev Gastroenterol Hepatol (2009) 0.86
Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol (2015) 0.86
Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. Eur J Clin Pharmacol (2010) 0.86
Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol (2016) 0.85
Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol (2006) 0.85
Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol (2011) 0.85
Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol (2016) 0.85
Meta-analysis: influence of host and viral factors in patients with chronic hepatitis C genotype 4 treated with pegylated interferon and ribavirin. Eur J Gastroenterol Hepatol (2014) 0.84
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One (2014) 0.84
Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLoS One (2013) 0.83
Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies. Hepat Med (2011) 0.83
Current therapy for hepatitis C. Int J Colorectal Dis (2005) 0.83
Management of chronic hepatitis C treatment failures: role of consensus interferon. Biologics (2009) 0.83
A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. World J Gastroenterol (2007) 0.82
The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in mice. Int J Physiol Pathophysiol Pharmacol (2016) 0.82
Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methods. Fibrogenesis Tissue Repair (2009) 0.81
Liver cirrhosis, transplantation and organ shortage. Dtsch Arztebl Int (2013) 0.81
A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. World J Gastroenterol (2009) 0.81
Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis. Hepat Mon (2011) 0.81
Long-term effects of antiviral therapy in patients with chronic hepatitis C. Hepat Res Treat (2010) 0.81
Reversal of cirrhosis: evidence-based medicine? Gastroenterology (2003) 0.80
Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C. World J Gastroenterol (2006) 0.80
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 7.35
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature (2011) 6.14
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A (2002) 4.52
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA (2013) 3.82
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology (2008) 3.82
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol (2004) 3.80
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology (2011) 3.55
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med (2012) 3.20
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med (2015) 2.77
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology (2010) 2.48
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg (2008) 2.20
Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl (2006) 2.01
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
Orlistat 60 mg reduces visceral adipose tissue: a 24-week randomized, placebo-controlled, multicenter trial. Obesity (Silver Spring) (2011) 1.84
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg (2011) 1.79
Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int (2008) 1.74
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol (2006) 1.72
Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol (2012) 1.71
Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: epidemiologic and biomolecular study. J Gastroenterol Hepatol (2006) 1.70
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol (2003) 1.62
Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology (2011) 1.59
Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. Gastroenterology (2002) 1.58
Malignant hepatic angiomyolipoma: report of a case and review of literature. Am J Surg Pathol (2008) 1.58
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology (2015) 1.55
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol (2005) 1.54
A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology (2007) 1.54
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology (2012) 1.53
Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg (2005) 1.52
Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys (2006) 1.51
Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology (2011) 1.49
Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis (2007) 1.47
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology (2003) 1.46
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology (2002) 1.40
Present status and perspectives of cell-based therapies for liver diseases. J Hepatol (2006) 1.33
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology (2005) 1.29
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest (2014) 1.29
Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 1.25
Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology (2012) 1.25
Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol (2004) 1.24
NHE3 inhibition by cAMP and Ca2+ is abolished in PDZ-domain protein PDZK1-deficient murine enterocytes. J Physiol (2007) 1.20
The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period. J Pediatr (2006) 1.19
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology (2003) 1.19
Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol (2008) 1.17
Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int (2005) 1.13
New therapeutic strategies for hepatitis C. Hepatology (2002) 1.12
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology (2002) 1.10
Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol (2002) 1.10
Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol (2006) 1.09
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant (2005) 1.08
A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res (2003) 1.08
Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis (2011) 1.08
Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. J Infect Dis (2008) 1.07
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology (2010) 1.07
Down regulation of small intestinal ion transport in PDZK1- (CAP70/NHERF3) deficient mice. Pflugers Arch (2007) 1.06
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol (2012) 1.05
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics (2003) 1.05
Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression. PLoS One (2012) 1.05
Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg (2006) 1.03
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology (2013) 1.02
p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci (2002) 1.02
The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci (2012) 1.01
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS (2009) 1.01
Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations. Eur Radiol (2004) 1.01
Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther (2008) 1.01
A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology (2004) 1.00